Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.50 USD
+0.18 (13.64%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.51 +0.01 (0.67%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Income Statements
Fiscal Year end for Enlivex Therapeutics Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 29 | 26 | 19 | 10 | 9 |
Income After Depreciation & Amortization | -29 | -26 | -19 | -10 | -9 |
Non-Operating Income | 0 | -5 | 5 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 2 | 1 |
Pretax Income | -29 | -31 | -14 | -12 | -9 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -31 | -14 | -12 | -9 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -31 | -14 | -12 | -9 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -29 | -25 | -19 | -10 | -8 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -29 | -26 | -19 | -10 | -9 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.58 | 18.40 | 17.86 | 13.17 | 8.65 |
Diluted EPS Before Non-Recurring Items | -1.56 | -1.69 | -0.81 | -0.90 | -1.11 |
Diluted Net EPS (GAAP) | -1.56 | -1.69 | -0.81 | -0.90 | -1.11 |
Fiscal Year end for Enlivex Therapeutics Ltd falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | NA | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | NA | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 10.33 | 5.63 | 6.65 | 6.79 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -10.33 | -5.63 | -6.65 | -6.79 |
Non-Operating Income | NA | 1.24 | -0.34 | -0.14 | -0.44 |
Interest Expense | NA | NA | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -9.10 | -5.96 | -6.79 | -7.22 |
Income Taxes | NA | NA | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -9.10 | -5.96 | -6.79 | -7.22 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -9.10 | -5.96 | -6.79 | -7.22 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 18.95 | 18.60 | 18.59 | 18.52 |
Diluted EPS Before Non-Recurring Items | NA | -0.48 | -0.32 | -0.37 | -0.39 |
Diluted Net EPS (GAAP) | NA | -0.48 | -0.32 | -0.37 | -0.39 |